Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life.
Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life.
复制标题
孕产妇 SARS-CoV-2 疫苗接种和婴儿在生命前六个月内针对 SARS-CoV-2 的保护。
DOI:
10.1038/s41467-023-36547-4
复制
发表时间:
2023-02-28
影响因子:
16.6
通讯作者:
Klein, Nicola P.
中科院分区:
文献类型:
--
作者:
Zerbo, Ousseny;Ray, G. Thomas;Fireman, Bruce;Layefsky, Evan;Goddard, Kristin;Lewis, Edwin;Ross, Pat;Omer, Saad;Greenberg, Mara;Klein, Nicola P.
We examined the effectiveness of maternal vaccination against SARS-CoV-2 infection in 30,311 infants born at Kaiser Permanente Northern California from December 15, 2020, to May 31, 2022. Using Cox regression, the effectiveness of ≥2 doses of COVID-19 vaccine received during pregnancy was 84% (95% confidence interval [CI]: 66, 93), 62% (CI: 39, 77) and 56% (CI: 34,71) during months 0–2, 0–4 and 0- 6 of a child’s life, respectively, in the Delta variant period. In the Omicron variant period, the effectiveness of maternal vaccination in these three age intervals was 21% (CI: −21,48), 14% (CI: −9,32) and 13% (CI: −3,26), respectively. Over the entire study period, the incidence of hospitalization for COVID-19 was lower during the first 6 months of life among infants of vaccinated mothers compared with infants of unvaccinated mothers (21/100,000 person-years vs. 100/100,000 person-years). Maternal vaccination was protective, but protection was lower during Omicron than during Delta. Protection during both periods decreased as infants aged. This study investigates the impact of maternal COVID-19 vaccination during pregnancy on infant infection during the first six months of life. Using data from California, USA, the authors find that protection against infection during the period of Delta dominance was high, but that it declined during the Omicron period.
登录
查看更多内容
影响因子:
5.1
作者:
Danino, Dana;Ashkenazi-Hoffnung, Liat;Diaz, Alejandro;Erps, Amir Dov;Eliakim-Raz, Noa;Avni, Yonat Shemer;Greenberg, David;Givon-Lavi, Noga;Youngster, Ilan
通讯作者:
Youngster, Ilan
DOI:
10.1056/nejmoa2034577
发表时间:
2020-12-31
期刊:
The New England journal of medicine
影响因子:
--
作者:
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者:
C4591001 Clinical Trial Group
DOI:
10.1056/nejmoa2119451
发表时间:
2022-04-21
期刊:
The New England journal of medicine
影响因子:
--
作者:
Andrews N;Stowe J;Kirsebom F;Toffa S;Rickeard T;Gallagher E;Gower C;Kall M;Groves N;O'Connell AM;Simons D;Blomquist PB;Zaidi A;Nash S;Iwani Binti Abdul Aziz N;Thelwall S;Dabrera G;Myers R;Amirthalingam G;Gharbia S;Barrett JC;Elson R;Ladhani SN;Ferguson N;Zambon M;Campbell CNJ;Brown K;Hopkins S;Chand M;Ramsay M;Lopez Bernal J
通讯作者:
Lopez Bernal J
影响因子:
5.5
作者:
Foppa, Ivo M.;Haber, Michael;Shay, David K.
通讯作者:
Shay, David K.
DOI:
10.15585/mmwr.mm7101e1
发表时间:
2022-01-07
期刊:
MMWR. Morbidity and mortality weekly report
影响因子:
--
作者:
Lipkind HS;Vazquez-Benitez G;DeSilva M;Vesco KK;Ackerman-Banks C;Zhu J;Boyce TG;Daley MF;Fuller CC;Getahun D;Irving SA;Jackson LA;Williams JTB;Zerbo O;McNeil MM;Olson CK;Weintraub E;Kharbanda EO
通讯作者:
Kharbanda EO